UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035504
Receipt number R000040438
Scientific Title Is muscle relaxant useful to facilitate insertion of LMA-Supreme: a prospective randomized controlled trial
Date of disclosure of the study information 2019/01/10
Last modified on 2019/12/17 10:24:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Is muscle relaxant useful to facilitate insertion of LMA-Supreme: a prospective randomized controlled trial

Acronym

Is muscle relaxant useful to facilitate insertion of LMA-Supreme: a prospective randomized controlled trial

Scientific Title

Is muscle relaxant useful to facilitate insertion of LMA-Supreme: a prospective randomized controlled trial

Scientific Title:Acronym

Is muscle relaxant useful to facilitate insertion of LMA-Supreme: a prospective randomized controlled trial

Region

Japan


Condition

Condition

breast cancer

Classification by specialty

Breast surgery Anesthesiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

This study is aimed at determining whether muscle relaxants facilitates insertion efficacy of the LMA-Supreme by novice doctors in anesthetized patients.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

the proportion of first attempt to successful insertion

Key secondary outcomes

sealing pressure, the number of attempts required for successful insertion, the incidence of sore throat and hoarseness one day after surgery,subjective difficulty of insertion


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Routine monitoring of electrocardiography, non-invasive blood pressure, pulse oximetry, and end-tidal carbon dioxide tension was performed. All patients are preoxygenated for 3 min with a total flow adjusted to 6 L/min. Anesthesia is induced with propofol 2.5mg/kg and fentanyl one microgram/kg. After loss of consciousness, rocuronium 0.3mg/kg is administered, and mask ventilation was performed with 5% sevoflurane for 90 seconds. SLMA is inserted 90 seconds after rocuronium administration. The SLMA is inserted and fixed according to the manufacturer's instructions. The size of SLMA is chosen based on the patient's body weight according to the manufacturer's instructions. Junior residents insert the SLMA. Intracuff pressure is adjusted to 60cmH2O using a cuff pressure monitor. Successful insertion is confirmed based on bilateral chest wall movement, normal capnograph curves, and sealing pressure of 15 cmH2O or over. If the third attempt is failed, this is recorded as a failure. At the end of insertion, the residents rate the difficulty using a visual analog scale, which ranges from 0mm (extremely easy) to 10mm (extremely difficult).

Interventions/Control_2

Routine monitoring of electrocardiography, non-invasive blood pressure, pulse oximetry, and end-tidal carbon dioxide tension was performed. All patients are preoxygenated for 3 min with a total flow adjusted to 6 L/min. Anesthesia is induced with propofol 2.5mg/kg and fentanyl one microgram/kg. After loss of consciousness, normal saline 0.03ml/kg is administered, and mask ventilation was performed with 5% sevoflurane for 90 seconds. SLMA is inserted 90 seconds after normal saline administration. The SLMA is inserted and fixed according to the manufacturer's instructions. The size of SLMA is chosen based on the patient's body weight according to the manufacturer's instructions. Junior residents insert the SLMA. Intracuff pressure is adjusted to 60cmH2O using a cuff pressure monitor. Successful insertion is confirmed based on bilateral chest wall movement, normal capnograph curves, and sealing pressure of 15 cmH2O or over. If the third attempt is failed, this is recorded as a failure. At the end of insertion, the residents rate the difficulty using a visual analog scale, which ranges from 0mm (extremely easy) to 10mm (extremely difficult).

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

the patiens who are going to have an elective mastectomy

Key exclusion criteria

any contraindication for the use of LMA, allergy to medication to be used during anesthesia, mouse opening <2.5cm, BMI>30, ASA-PS>3

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takaya Hojo

Organization

Tokyo Metropolitan Tama Medical Center

Division name

Department of Anaesthesia

Zip code


Address

2-8-29 Musashidai, Fuchu-shi, Tokyo

TEL

042-323-5111

Email

ha_hi_hu_he_hojo@yahoo.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takaya Hojo

Organization

Tokyo Metropolitan Tama Medical Center

Division name

Department of Anaesthesia

Zip code


Address

2-8-29 Musashidai, Fuchu-shi, Tokyo

TEL

042-323-5111

Homepage URL


Email

ha_hi_hu_he_hojo@yahoo.co.jp


Sponsor or person

Institute

Tokyo Metropolitan Tama Medical Center

Institute

Department

Personal name



Funding Source

Organization

Tokyo Metropolitan

Organization

Division

Category of Funding Organization

Local Government

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京都立多摩総合医療センター


Other administrative information

Date of disclosure of the study information

2019 Year 01 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 10 Month 01 Day

Date of IRB

2018 Year 10 Month 01 Day

Anticipated trial start date

2019 Year 01 Month 10 Day

Last follow-up date

2019 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 01 Month 10 Day

Last modified on

2019 Year 12 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040438


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name